EkoSonic® endovascular system and other catheter-directed treatment reperfusion strategies for acute pulmonary embolism: overview of efficacy and safety outcomes. (2nd August 2020)

• Record Type: Journal Article
• Authors: Hobohm, Lukas; Keller, Karsten; Münzel, Thomas; Gori, Tommaso; Konstantinides, Stavros V.
• Is Part Of: Expert review of medical devices. Volume 17:Number 8(2020)
• Page Start: 739
• Page End: 749
• Publication Date: 2020-08-02
• Subjects: Pulmonary embolism -- catheter-directed treatment -- ultrasound-accelerated thrombolysis -- Ekosonic® endovascular system; Medical instruments and apparatus -- Periodicals; 610.28
• DOI: 10.1080/17434440.2020.1796632
• Languages: English
• ISSNs: 1743-4440

Abstract

ABSTRACT: Introduction: Studies performed in the past decade suggested that evolving reperfusion strategies may improve early outcomes of patients with acute pulmonary embolism (PE) and hemodynamic decompensation. In this regard, catheter-directed treatment (CDT) options are receiving increasing attention. Areas covered: A broad spectrum of CDT options exists for the treatment of patients with acute PE. Procedures include catheter-directed local thrombolysis with or without ultrasound assistance, catheter-directed mechanical or suction embolectomy, and combined pharmaco-mechanical approaches. We present here an overview of the available CDT techniques, focusing on the EkoSonic® endovascular system. Expert commentary: CDT, particularly local ultrasound accelerated thrombolysis, continues to evolve. Its increasing popularity is the result of accumulating promising results, which suggest a relief of right ventricular (RV) pressure overload and improvement of RV function. These favorable effects on surrogate endpoints were accompanied by a low rate of procedure-related adverse events, notably intracranial hemorrhage. Although the overall risk of serious bleeding appears to be low in CDT, the lack of direct comparisons with other reperfusion options does not allow definitive conclusions. Prospective controlled trials with robust clinical outcomes are urgently needed to establish the postulated benefits of CDT in selected patients with acute PE.